AU · rank #9 · 2026-09-07
FRE
XETRA · EUR · $30.21B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 1.590 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.05 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 10 |
| Insider signal (90d) | — |
| Analyst upside Consensus target $55.59 | +27.4% |
| Momentum acceleration 3-month minus 12-month momentum. | +18.43% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.50 |
| Gross margin TTM | +25.4% |
| 52w high | $51.53 |
| Market cap (USD) | $30.21B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Fresenius SE & Co. KGaA is a global healthcare group providing system-critical pharmaceutical and medical technology products through Fresenius Kabi alongside extensive private hospital operations via Fresenius Helios.
Rationale
Strong Q4 2025 earnings and robust 2026 constant-currency Core EPS growth guidance of 5–10% have fueled 10 net positive upward revisions and a 91.7% revision agreement, reinforcing the model's 27.4% target upside.
Material risks
- 1Operational margin compression across the Helios and Kabi segments due to persistent clinical labor shortages, wage inflation, or government-mandated healthcare reimbursement cuts in Germany and Spain.
- 2Execution delays or elevated integration costs associated with transitioning to the REJUVENATE phase of its simplified #FutureFresenius organizational model.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.